Cost Estimator

Cost Estimator — The Development Budget Architect

The second pillar of biotech valuation — after revenue — is cost. An rNPV model requires probability-weighted cash outflows at each development phase, and the range between a lean biotech program and a fully loaded pharma program can be 5-10x. This skill produces defensible cost estimates by phase, grounded in Tufts CSDD benchmarks, CRO pricing data, and therapeutic-area-specific complexity factors.

Getting costs right matters for two reasons: it determines how much capital a company needs to raise (dilution risk) and it sets the denominator for return-on-investment calculations that drive deal economics.

How to Run

Input

Steps

Benchmark data: For sourced capitalized-vs-out-of-pocket cost ranges (DiMasi / Wouters / ASPE), the 3.6–4.6× therapeutic-area spread, per-study trial costs by phase, and success-rate context, use references/development-cost-benchmarks.md. Always state method, base year, and out-of-pocket vs capitalized when quoting a cost-per-drug figure.

Step 1 — Establish Phase-by-Phase Cost Benchmarks

Start with industry median costs by phase. These benchmarks derive from Tufts CSDD, DiMasi et al. (Journal of Health Economics, 2016), and updated with 2023-2025 CRO market data:

Tufts CSDD framework context: DiMasi et al. estimated the fully capitalized cost of developing a new drug at $2.6B (2013 dollars, ~$3.2B in 2025 dollars). This includes failures — the cost of the ~90% of programs that never reach approval amortized across the ~10% that do. For a single program cost estimate, use the direct out-of-pocket costs above, not the fully loaded figure.

Step 2 — Apply Therapeutic Area Multipliers

Clinical trial costs vary significantly by therapeutic area due to differences in trial complexity, patient availability, and endpoint requirements:

Step 3 — Model Cost Drivers in Detail

For each phase, assess the specific cost drivers:

Clinical Operations (50-60% of trial cost):

CMC / Manufacturing (10-20% of program cost):

CRO vs. In-House Execution:

Step 4 — Estimate Regulatory Costs

Regulatory strategy impact on cost:

• Accelerated Approval: Saves 1-2 years of development time; requires confirmatory trial (add $50-200M post-approval)
• Breakthrough Therapy: Does not reduce trial cost but compresses timelines by 30-40% (reduces time-cost-of-capital)
• Orphan Drug: Smaller trials but still requires adequate safety database; fee waivers save $1-3M

Step 5 — Estimate Launch and Commercialization Costs

Launch models by company type:

• Virtual biotech with partner: $0 (partner bears commercial cost; company receives royalties/milestones)
• Co-commercialization: $50-100M first year; split with partner
• Independent launch (specialty): $100-200M first year
• Independent launch (primary care): $300-500M+ first year (large field force required)

Step 6 — Compile Development Cost Timeline

Output

DEVELOPMENT COST ESTIMATE — [Asset Name]
Indication: [disease]
Modality: [type]
Current Phase: [phase]
Date: [assessment date]

PHASE-BY-PHASE COST TIMELINE:

Phase          | Duration  | Cost ($M)        | Cumulative ($M)  | Key Assumptions
──────────────────────────────────────────────────────────────────────────────────
IND-enabling   | 12-18mo   | $[X]-[Y]        | $[X]-[Y]         | [CMC, tox studies]
Phase 1        | 12-18mo   | $[X]-[Y]        | $[X]-[Y]         | [dose escalation design]
Phase 2        | 18-24mo   | $[X]-[Y]        | $[X]-[Y]         | [N patients, endpoints]
Phase 3        | 24-36mo   | $[X]-[Y]        | $[X]-[Y]         | [N patients, sites, geography]
Regulatory     | 12-18mo   | $[X]-[Y]        | $[X]-[Y]         | [filing strategy]
Launch (Yr 1)  | 12mo      | $[X]-[Y]        | $[X]-[Y]         | [field force, market access]
──────────────────────────────────────────────────────────────────────────────────
TOTAL PRE-APPROVAL:         $[X]-[Y]M
TOTAL THROUGH LAUNCH:       $[X]-[Y]M

COGS ESTIMATE (POST-APPROVAL):
  Modality: [type]
  COGS as % of net revenue: [X]-[Y]%
  Gross margin: [X]-[Y]%

COGS BENCHMARKS:
  Small molecule:    10-20% COGS (80-90% gross margin)
  Monoclonal antibody: 15-25% COGS (75-85% gross margin)
  ADC:               20-30% COGS (70-80% gross margin)
  Cell therapy:      30-50% COGS (50-70% gross margin)
  Gene therapy:      15-25% COGS (75-85% gross margin) — high fixed, low variable

CAPITAL REQUIREMENT ANALYSIS:
  Cash needed to next value inflection: $[X]M
  Value inflection: [Phase 2 data / Phase 3 interim / NDA filing]
  Months to inflection: [X]
  Implied monthly burn rate: $[X]M/mo

KEY COST RISKS:
  1. [Enrollment risk — screen failure rate or site activation delays]
  2. [CMC risk — manufacturing scale-up complexity]
  3. [Comparator cost risk — expensive active comparator required]

Error Handling

Cross-Domain Connections

• Biotech-venture/peak-sales-forecaster: Revenue minus costs drives NPV; cost timing affects discount factor weighting
• Biotech-venture/pos-calculator: Failed program costs are sunk; PoS determines expected cost per successful drug
• Biotech-venture/deal-economics: Development costs inform upfront/milestone structure; cost-sharing in partnerships
• Biotech-venture/asset-valuation: Cost timeline is the negative cash flow stream in rNPV models
• Biotech-venture/manufacturing-ip: CMC costs and COGS connect to manufacturing strategy and IP protection